The Lancet Oncology in conversation with Podcast Por The Lancet Group arte de portada

The Lancet Oncology in conversation with

The Lancet Oncology in conversation with

De: The Lancet Group
Escúchala gratis

Editors at The Lancet Oncology, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.

A monthly audio companion to the journal, this podcast covers a broad range of topics, from early-stage breast cancer treatment to mRNA vaccines, the access to essential cancer medicines for children to measuring ovarian toxicity, and more.

© 2025 The Lancet Group Ciencia Ciencias Biológicas Enfermedades Físicas Higiene y Vida Saludable
Episodios
  • Andre Pfob and Peter Dubsky on The Lucerne Toolbox 3

    Andre Pfob and Peter Dubsky on The Lucerne Toolbox 3
    Nov 25 2025

    Dr Andre Pfob (Department of Obstetrics & Gynecology, Heidelberg University Hospital) and Prof Peter Dubsky (Faculty of Health Sciences and Medicine, University of Lucerne) discuss their Review entitled The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer—a multidisciplinary consensus.

    Click here to read the full article: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00463-2/fulltext

    Tell us what you thought about this episode

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    Más Menos
    26 m
  • Gary Rodin on The human crisis in cancer: a Lancet Oncology Commission

    Gary Rodin on The human crisis in cancer: a Lancet Oncology Commission
    Nov 2 2025

    Dr Gary Rodin discusses The human crisis in cancer: a Lancet Oncology Commission which identifies a growing imbalance between technological innovation and the human dimensions of cancer care.

    Click here to read the full Commission: The human crisis in cancer: a Lancet Oncology Commission

    And comment: Re-establishing human-centred care


    Tell us what you thought about this episode

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    Más Menos
    11 m
  • Matthias Preusser on the phase 2 TUXEDO-3 trial

    Matthias Preusser on the phase 2 TUXEDO-3 trial
    Oct 27 2025

    Deputy Editor Ali Landman speaks with Matthias Preusser (Medical University of Vienna, Vienna, Austria) about two reports from the phase 2 TUXEDO-3 trial investigating patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breast cancer or non-small-cell lung cancer.

    Hear about the potential of HER3-targeted antibody-drug conjugates for brain metastases, why recruiting patients with active brain metastases to clinical trials is so important, and where the field is going next.

    Click here to read the full article: Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial

    Click here to read the full article: Patritumab deruxtecan (HER3-Dxd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial

    Tell us what you thought about this episode

    Continue this conversation on social!
    Follow us today at...
    https://thelancet.bsky.social/
    https://instagram.com/thelancetgroup
    https://facebook.com/thelancetmedicaljournal
    https://linkedIn.com/company/the-lancet
    https://youtube.com/thelancettv
    Más Menos
    17 m
Todavía no hay opiniones